KR950005324A - 인슐린 제제 - Google Patents

인슐린 제제 Download PDF

Info

Publication number
KR950005324A
KR950005324A KR1019940019550A KR19940019550A KR950005324A KR 950005324 A KR950005324 A KR 950005324A KR 1019940019550 A KR1019940019550 A KR 1019940019550A KR 19940019550 A KR19940019550 A KR 19940019550A KR 950005324 A KR950005324 A KR 950005324A
Authority
KR
South Korea
Prior art keywords
insulin
formulation
zinc
ultralente
crystals
Prior art date
Application number
KR1019940019550A
Other languages
English (en)
Inventor
아더 호프만 제임스
Original Assignee
피터 지. 스트링거
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피터 지. 스트링거, 일라이 릴리 앤드 캄파니 filed Critical 피터 지. 스트링거
Publication of KR950005324A publication Critical patent/KR950005324A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 울트라렌테(Ultralente) 결정 및 제제중의 전체 아연 농도가 인슐린 100 단위당 약 0.5내지 약 20㎎인 현탁액을 포함하는 인슐린 제제에 관한 것이다. 상기 제제중에서 전체 아연의 50% 이상이 인슐린과 착물을 형성하기 보다는 가용성 분획에 존재한다. 이 인슐린 제제는 일반적으로 약 6.0 내지 약 7.4의 pH를 갖는다. 또한 본 발명의 인슐린 제제는 프로타민과 같은 다른 단백질을 함유하지 않는다. 이 아연-개질된 제제는 매우 오래 지속되는 인간 인슐린 생성물의 특성을 나타낸다.

Description

인슐린 제제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (3)

  1. 제제 중의 전체 아연 농도가 인슐린 100단위당 약 0.5 내지 약 20㎎인 울트라렌테(Ultralente) 인슐린 결정의 현탁액을 포함하는 인간 인슐린 제제.
  2. 제제 중의 전체 아연 농도가 인슐린 100단위당 약 0.5 내지 약 7㎎인 울트라렌테 인슐린 결정의 현탁액, 방부제, 등장제 및 완충액을 포함하는 인간 인슐린 제제
  3. 아연과 울트라렌테 인슐린 결정을 혼합하는 것을 포함하는, 제1항 또는 제2항에 따르는 인슐린 제제의 제조방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940019550A 1993-08-13 1994-08-09 인슐린 제제 KR950005324A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8/106,106 1993-08-13
US08/106,106 US5534488A (en) 1993-08-13 1993-08-13 Insulin formulation

Publications (1)

Publication Number Publication Date
KR950005324A true KR950005324A (ko) 1995-03-20

Family

ID=22309529

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940019550A KR950005324A (ko) 1993-08-13 1994-08-09 인슐린 제제

Country Status (27)

Country Link
US (1) US5534488A (ko)
EP (1) EP0646379B1 (ko)
JP (1) JPH07149660A (ko)
KR (1) KR950005324A (ko)
CN (1) CN1109364A (ko)
AT (1) ATE207761T1 (ko)
AU (1) AU674975B2 (ko)
BR (1) BR9403204A (ko)
CA (1) CA2129763A1 (ko)
CO (1) CO4230235A1 (ko)
CZ (1) CZ193794A3 (ko)
DE (1) DE69428860T2 (ko)
DK (1) DK0646379T3 (ko)
ES (1) ES2164691T3 (ko)
HU (1) HUT67853A (ko)
IL (1) IL110581A0 (ko)
NO (1) NO942959L (ko)
NZ (1) NZ264197A (ko)
PE (1) PE14495A1 (ko)
PH (1) PH30757A (ko)
PL (1) PL177002B1 (ko)
PT (1) PT646379E (ko)
RU (1) RU2135205C1 (ko)
TW (1) TW326394B (ko)
UA (1) UA27874C2 (ko)
YU (1) YU50494A (ko)
ZA (1) ZA945939B (ko)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578238A (en) * 1992-10-30 1996-11-26 Lord Corporation Magnetorheological materials utilizing surface-modified particles
YU18596A (sh) * 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
US6531448B1 (en) * 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
EP1396272A1 (en) * 1997-12-23 2004-03-10 Eli Lilly & Company Insoluble Insulin Compositions for Controlling Blood Glucose
US6956021B1 (en) * 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
WO2001000675A1 (en) * 1999-06-29 2001-01-04 Eli Lilly And Company Protamine-free insoluble acylated insulin compositions
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
EP1265630B1 (en) * 2000-03-24 2006-06-07 Genentech, Inc. Use of insulin for the treatment of cartilagenous disorders
JP4303959B2 (ja) * 2000-10-06 2009-07-29 ジ アドバイザー − ディフェンス リサーチ アンド ディベラップメント オーガナイゼイション 磁気感受性流体組成物およびその調製方法
US6875368B2 (en) * 2000-11-29 2005-04-05 The Adviser Defence Research And Development Organisation, Ministry Of Defence, Government Of India Magnetorheological fluid composition and a process for preparation thereof
DK1358209T3 (da) * 2001-02-09 2007-05-07 Genentech Inc Krystallisering af IGF-1
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
ES2412306T3 (es) 2002-01-09 2013-07-11 Emisphere Technologies, Inc. Polimorfos de 4-((4-cloro-2-hidroxibenzoil)amino)butanoato de sodio
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
JP4601627B2 (ja) * 2004-01-16 2010-12-22 バイオデル， インコーポレイテッド 舌下薬物送達デバイス
PT1740154E (pt) * 2004-03-12 2009-09-11 Biodel Inc Composições de insulina com absorção melhorada
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
US20080090753A1 (en) * 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US20080085298A1 (en) * 2004-03-12 2008-04-10 Biodel, Inc. Rapid Mucosal Gel or Film Insulin Compositions
ES2729825T3 (es) 2004-05-06 2019-11-06 Emisphere Tech Inc Formas poliméricas cristalinas de N-[8-(2-hidroxibenzoil)amino]caprilato monosódico
NZ551241A (en) * 2004-05-14 2010-08-27 Emisphere Tech Inc Aryl ketone compounds and compositions for delivering active agents
EP2626368B1 (en) 2004-07-19 2016-12-21 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
EP2248531A1 (en) 2004-08-03 2010-11-10 Emisphere Technologies, Inc. Antidiabetic oral insulin-biguanide combination
US20060078623A1 (en) * 2004-08-13 2006-04-13 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
US7713929B2 (en) * 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US8084420B2 (en) * 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
JP2009533471A (ja) * 2006-04-12 2009-09-17 バイオデル， インコーポレイテッド 即効型および長時間作用型組合せインスリン製剤
ES2841379T3 (es) 2007-03-13 2021-07-08 Jds Therapeutics Llc Procedimientos y composiciones para la liberación sostenida de cromo
WO2008124522A2 (en) * 2007-04-04 2008-10-16 Biodel, Inc. Amylin formulations
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
BRPI0818004B8 (pt) 2007-10-16 2021-05-25 Biocon Ltd composição farmacêutica sólida administrável por via oral e o processo da mesma.
CN101951957A (zh) * 2008-01-04 2011-01-19 百达尔公司 胰岛素释放作为组织的葡萄糖水平的函数的胰岛素制剂
LT2349324T (lt) 2008-10-17 2017-12-27 Sanofi-Aventis Deutschland Gmbh Insulino ir glp-1 agonisto derinys
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
ES2534191T3 (es) 2009-11-13 2015-04-20 Sanofi-Aventis Deutschland Gmbh Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
PL2498801T3 (pl) 2009-11-13 2018-08-31 Sanofi Aventis Deutschland Kompozycja farmaceutyczna zawierająca desPro<sup>36</sup>eksendyno-4(1-39)-Lys6-NH2 i metioninę
WO2011103575A1 (en) * 2010-02-22 2011-08-25 Case Western Reserve University Long-acting insulin analogue preparations in soluble and crystalline forms
HUE031181T2 (en) 2010-08-30 2017-06-28 Sanofi Aventis Deutschland Use of AVE0010 for the manufacture of a medicament for the treatment of type 2 diabetes
KR101836957B1 (ko) 2011-03-01 2018-03-09 제이디에스 테라퓨틱스, 엘엘씨 당뇨병, 저혈당 및 관련 장애를 치료 및 예방하기 위한 인슐린과 크롬을 포함하는 조성물
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
US9950039B2 (en) 2014-12-12 2018-04-24 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
MX2018009748A (es) 2016-02-11 2019-02-07 Nutrition 21 Llc Composiciones que contienen cromo para mejorar la salud y el estado físico.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2626228A (en) * 1945-05-17 1953-01-20 Novo Terapeutisk Labor As Method of producing crystalline insulin
US2882202A (en) * 1950-04-05 1959-04-14 Novo Terapeutisk Labor As Insulin crystal preparations and methods of producing them
US2882203A (en) * 1951-06-26 1959-04-14 Novo Terapeutisk Labor As Injectable insulin preparation with protracted effect
US2849370A (en) * 1953-06-04 1958-08-26 Novo Terapeutisk Labortorium A Injectable insulin preparations with protracted effect and process of producing same
US3102077A (en) * 1953-08-19 1963-08-27 Christensen Henry Marinus Preparation of insulin containing 2.75 to 8 percent zinc content
US2819999A (en) * 1953-11-13 1958-01-14 Novo Terapeutisk Labor As Process for crystallization of insulin using freeze dried insulin as seeding material
US2799622A (en) * 1953-11-14 1957-07-16 Novo Terapeutisk Labor As Process of producing insulin crystals of substantially uniform size and compositions thereof
US3060093A (en) * 1957-07-18 1962-10-23 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form and method of preparation
DE2933946A1 (de) * 1979-08-22 1981-03-12 Hoechst Ag, 6000 Frankfurt Insulinkristallsuspension und verfahren zu ihrer herstellung.
FI78616C (fi) * 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
PH23446A (en) * 1986-10-20 1989-08-07 Novo Industri As Peptide preparations
DE3827533A1 (de) * 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus

Also Published As

Publication number Publication date
PL177002B1 (pl) 1999-09-30
JPH07149660A (ja) 1995-06-13
PE14495A1 (es) 1995-06-02
TW326394B (en) 1998-02-11
HUT67853A (en) 1995-05-29
AU674975B2 (en) 1997-01-16
PT646379E (pt) 2002-03-28
PL304600A1 (en) 1995-02-20
UA27874C2 (uk) 2000-10-16
CZ193794A3 (en) 1995-03-15
CN1109364A (zh) 1995-10-04
YU50494A (sh) 1997-01-08
BR9403204A (pt) 1995-04-18
EP0646379B1 (en) 2001-10-31
CO4230235A1 (es) 1995-10-19
ZA945939B (en) 1996-02-08
RU2135205C1 (ru) 1999-08-27
CA2129763A1 (en) 1995-02-14
NZ264197A (en) 1997-01-29
DE69428860T2 (de) 2002-05-02
IL110581A0 (en) 1994-11-11
US5534488A (en) 1996-07-09
PH30757A (en) 1997-10-17
ES2164691T3 (es) 2002-03-01
DE69428860D1 (de) 2001-12-06
NO942959D0 (no) 1994-08-09
DK0646379T3 (da) 2001-12-03
EP0646379A1 (en) 1995-04-05
NO942959L (no) 1995-02-14
AU7024794A (en) 1995-02-23
ATE207761T1 (de) 2001-11-15
HU9402287D0 (en) 1994-09-28

Similar Documents

Publication Publication Date Title
KR950005324A (ko) 인슐린 제제
AU2173988A (en) Stabilised human protein preparations
ES2139360T3 (es) Preparaciones de suspensiones de peptidos o proteinas.
CA2155005A1 (en) Pharmaceutical Compositions Containing Bactericidal Permeability Increasing Protein and a Surfactant
CA2050786A1 (en) An antimicrobial peptide and an antimicrobial composition
AU2275188A (en) Inductive collagen-based bone repair preparations
CA2113995A1 (en) Use of gentisic acid or gentisyl alcohol for stabilising radiolabeled peptides and proteins
CA2075060A1 (en) Novel vehicle gases and their use in medical preparations
ATE146360T1 (de) Gonadotropin enthaltende gefriergetrocknete troepfen
AU8139794A (en) Cosmetic or dermatological oil-in-water emulsions containing amino acids and inorganic pigments
CA2070647A1 (en) Use of an anticoagulant as a diagnostic agent
AU629445B2 (en) Improvements in or relating to topical compositions containing 1 alpha 25-dihydroxycholecalciferol
AU8375891A (en) Antioxidant system based on a basic amino acid in combination with a tocopherol or derivative thereof and a nonthiolated polypeptide, and compositions containing the same
KR920018076A (ko) 신규 폴리펩티드
WO1996036220A3 (en) Insecticidal composition containing diatomaceous earth and silica
EP0063328A3 (en) Compositions containing secretin and method for preventing the adsorption of secretin
CA2153071A1 (en) Derivatized calcitonins
AU7533394A (en) Antiacid pharmaceutical composition in the form of a suspension based on sucralphate gel
TH17521A (th) สูตรผสมอินซูลิน
TH17521EX (th) สูตรผสมอินซูลิน

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
NORF Unpaid initial registration fee